[Tissue polypeptide antigen as a tumor marker for gynecologic malignancies]. 1985

M Inoue, and Y Fujita, and Y Abe, and Y Inoue, and G Ueda, and O Tanizawa, and J Minagawa, and T Yamada, and K Ohashi, and M Ozaki

Tissue polypeptide antigen (TPA) was measured by radioimmunoassay in sera from 413 patients with various gynecologic tumors. The distribution of positive values (greater than 102 U/l) in the patients with gynecologic malignancies was such that the percentage of patients with elevated values appeared to increase with advancing stages of disease. Among the cervical cancer patients, elevated TPA values were observed in 11% of preinvasive, 35% of stage I and 67% of advanced cases. Similarly, the TPA values were elevated in 35% of the endometrial cancer patients. Among the patients with ovarian malignancies, serum TPA was elevated in 33% of borderline, 47% of stage I and 86% of advanced cases. However, serum TPA was elevated in 21% of patients with uterine myomas and in 12% of those with ovarian benign tumors. The serial measurements of TPA in sera of the patients with gynecologic malignancies showed that serum TPA levels correlated with the effect of treatment and the clinical courses. The present observations demonstrate that the lack of tumor specificity of TPA limits its diagnostic value in gynecologic malignancies but that serial measurements of this antigen appear to be useful for monitoring of patients.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Inoue, and Y Fujita, and Y Abe, and Y Inoue, and G Ueda, and O Tanizawa, and J Minagawa, and T Yamada, and K Ohashi, and M Ozaki
October 1984, Nihon Sanka Fujinka Gakkai zasshi,
M Inoue, and Y Fujita, and Y Abe, and Y Inoue, and G Ueda, and O Tanizawa, and J Minagawa, and T Yamada, and K Ohashi, and M Ozaki
February 1982, Medicina clinica,
M Inoue, and Y Fujita, and Y Abe, and Y Inoue, and G Ueda, and O Tanizawa, and J Minagawa, and T Yamada, and K Ohashi, and M Ozaki
September 1984, Neurologia medico-chirurgica,
M Inoue, and Y Fujita, and Y Abe, and Y Inoue, and G Ueda, and O Tanizawa, and J Minagawa, and T Yamada, and K Ohashi, and M Ozaki
February 1990, Nihon rinsho. Japanese journal of clinical medicine,
M Inoue, and Y Fujita, and Y Abe, and Y Inoue, and G Ueda, and O Tanizawa, and J Minagawa, and T Yamada, and K Ohashi, and M Ozaki
January 1996, Anticancer research,
M Inoue, and Y Fujita, and Y Abe, and Y Inoue, and G Ueda, and O Tanizawa, and J Minagawa, and T Yamada, and K Ohashi, and M Ozaki
March 1984, Gan no rinsho. Japan journal of cancer clinics,
M Inoue, and Y Fujita, and Y Abe, and Y Inoue, and G Ueda, and O Tanizawa, and J Minagawa, and T Yamada, and K Ohashi, and M Ozaki
January 2000, Anticancer research,
M Inoue, and Y Fujita, and Y Abe, and Y Inoue, and G Ueda, and O Tanizawa, and J Minagawa, and T Yamada, and K Ohashi, and M Ozaki
January 2004, Voprosy onkologii,
M Inoue, and Y Fujita, and Y Abe, and Y Inoue, and G Ueda, and O Tanizawa, and J Minagawa, and T Yamada, and K Ohashi, and M Ozaki
January 2002, Anticancer research,
M Inoue, and Y Fujita, and Y Abe, and Y Inoue, and G Ueda, and O Tanizawa, and J Minagawa, and T Yamada, and K Ohashi, and M Ozaki
December 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!